Press Releases
Press Releases
Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
Outlines actions underway to accelerate launch of Entrestoยฎ, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyxยฎ Highlights leading pipeline of second generation immuno-oncology assets. Confirms Sandoz on track for...
Press Releases
FDA Recommends Approval Of Sanofi Treatment For Adults With Type 2 Diabetes
Sanofi announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. FDA recommended the approval of the NDA for the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the...
Press Releases
GSK, Fondazione Telethon and Ospedale San Raffaele announce publication of pivotal safety and efficacy of gene therapy for children with ADA-SCID
GSK, Fondazione Telethon and Ospedale San Raffaeletoday announced the publication in BLOOD of the long-term safety and efficacy data from an analysis of 18 children with ADA-SCID treated. with hematopoietic stem cell gene therapy between 2000...
Press Releases
Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%
Allergan plc announced that the New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults, has been accepted by the U.S....
Press Releases
Seqirus receives FDA approval for FLUCELVAX QUADRIVALENT
CSL announced that the US FDA has approved Seqirusโ FLUCELVAX QUADRIVALENTโข (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. FLUCELVAX QUADRIVALENT helps protect against the two...
Press Releases
Rituximab regulatory submission accepted by European Medicines
Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product's label. Sandoz' submission includes data from multiple clinical trials...
Press Releases
FDA Expands Invokamet Label to Include First-Line Treatment of with type 2 diabetes
Janssen Pharmaceuticals, Inc announced the U.S. FDA has approved INVOKAMETยฎ, a fixed-dose combination therapy of INVOKANAยฎ (canagliflozin) and metformin hydrochloride, for first-line treatment of adults with type 2 diabetes. With this new approval, INVOKAMETยฎ may now...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.














